Research location
Avellino
Italy
Advertisement
Research activity in Avellino
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 84 trials and 84 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Avellino
84 linked trials · page 1 of 2A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World SettingNCT07230691 · 2025-12-03 · 1 site observation
RECRUITING
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05 · 1 site observation
RECRUITING
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation
RECRUITING
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation
RECRUITING
EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly PhaseNCT06894173 · 2022-12-03 · 1 site observation
RECRUITING
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in ItalyNCT06948396 · 2025-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)NCT06726265 · 2025-03-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)NCT05862545 · 2023-06-01 · 1 site observation
COMPLETED
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)NCT05526755 · 2023-03-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationNCT05609578 · 2022-11-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · 2022-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNCT05502237 · 2022-10-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399 · 2022-08-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)NCT05546905 · 2022-06-23 · 1 site observation
COMPLETED
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCNCT04681131 · 2021-03-17 · 1 site observation
COMPLETED
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationNCT04685135 · 2021-02-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyNCT04655976 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerNCT04475939 · 2020-10-26 · 1 site observation
COMPLETED
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080 · 2020-09-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerNCT04362072 · 2020-09-29 · 1 site observation
COMPLETED
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).NCT04303780 · 2020-06-04 · 1 site observation
COMPLETED
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerNCT04194944 · 2020-02-17 · 1 site observation
ACTIVE_NOT_RECRUITING
SyncAV Post-Market TrialNCT04100148 · 2019-10-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)NCT03976375 · 2019-06-26 · 1 site observation
COMPLETED
Crizotinib in ALK Rearranged Non-small-cell Lung CancerNCT04317651 · 2019-05-16 · 1 site observation
UNKNOWN
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT03693300 · 2019-04-16 · 1 site observation
COMPLETED
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)NCT03829332 · 2019-03-13 · 1 site observation
COMPLETED
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibNCT03778229 · 2019-01-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNCT03539536 · 2018-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)NCT03631706 · 2018-10-01 · 1 site observation
COMPLETED
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung CancerNCT03439215 · 2017-06-13 · 1 site observation
UNKNOWN
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.NCT03084471 · 2017-06-05 · 1 site observation
COMPLETED
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)NCT02941601 · 2016-11-01 · 1 site observation
WITHDRAWN
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).NCT02831959 · 2016-07-01 · 1 site observation
COMPLETED
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsNCT02737501 · 2016-05-26 · 1 site observation
COMPLETED
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerNCT02633189 · 2016-04-01 · 1 site observation
UNKNOWN
Observational Study On The Characterization Of 24-Hour Symptoms In Patients With COPDNCT03105999 · 2016-02-01 · 1 site observation
COMPLETED
SATisfaction and Adherence to COPD TreatmentNCT02689492 · 2015-12-11 · 1 site observation
COMPLETED
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyNCT02538666 · 2015-10-13 · 1 site observation
COMPLETED
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCNCT02474355 · 2015-09-18 · 1 site observation
COMPLETED
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT02477826 · 2015-08-05 · 1 site observation
COMPLETED
Pre-operative Very Low-calorie Protein-based Versus Hypocaloric Enteral NutritionNCT02418975 · 2015-04-01 · 1 site observation
UNKNOWN
Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)NCT02499614 · 2014-12-01 · 1 site observation
UNKNOWN
AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT02151981 · 2014-08-04 · 1 site observation
COMPLETED
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung CancerNCT02106546 · 2014-04-10 · 1 site observation
COMPLETED
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)NCT02041533 · 2014-03-27 · 1 site observation
COMPLETED
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung CancerNCT02027428 · 2014-02-11 · 1 site observation
COMPLETED
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)NCT01853826 · 2013-07-17 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.